Stopping Antibiotics Early in Patients 65 and Older Hospitalized for Viral Lung Infections

What this Trial Is About

Researchers are studying antibiotic use in elderly patients hospitalized with viral respiratory infections such as influenza, parainfluenza, RSV, and SARS-CoV-2. These infections carry a high risk of mortality, especially when complicated by bacterial co-infections, which significantly increase death risk. The study aims to provide strong evidence on whether stopping antibiotics early in viral infections is safe or potentially harmful, addressing the common overuse of antibiotics in these cases. Participants are assigned to one of two groups one where antibiotics are stopped early based on viral or negative test results, and a standard care group where antibiotics are given as usual. The standard antibiotics include Amoxicillin-clavulanic acid, Ceftriaxone, Piperacillin-Tazobactam, or Pristinamycin, each administered for seven days with specified doses. The study begins with hospitalization and microbiological testing within 48 hours and monitors patients during their hospital stay. Throughout the study, researchers track the number of days patients go without antibiotics over 30 days, antibiotic side effects, mortality at 30 and 180 days, and length of hospital stay. Patient consent is required, and evaluations include clinical signs, imaging tests, and microbiological samples. The total participation may extend up to six months for mortality follow-up, ensuring comprehensive safety and outcome monitoring.

Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection